Angelman syndrome is a debilitating genetic disorder that occurs in more than one in every 15,000 live births. Monitoring participants' biological clocks may be the quickest way to determine the effectiveness of experimental drugs currently under development to treat Angelman syndrome. That is one of the implications of a study published in the Feb. 5 issue of the journal iCurrent Biology/i which establishes a molecular-level link between a slow-down in the ...
via Medindia Health News More READ
via Medindia Health News More READ
Lake forest health and fitness http://ift.tt/1G6RSEB
No comments:
Post a Comment